FOI Request
- Disclosure ID
- FOI/02446
- Request Date
- May 17, 2018
- Subject
- Drug Usage [May 17' - May 18']
- Description
Could you please provide me with the following numbers of patients treated in the last 12 months (latest 12 months possible) with the following drugs for either Rheumatology, Dermatology or Gastroenterology departments.
- Response
Pharmacy does not hold information on the indication for the use of the medicines, so where the use may be for several indications in for example oncology/haematology/gastroenterology, we are not able to state number of patients, so it has been recorded as Not known. Data is only available from pharmacy system and may not represent actual use in each speciality.
Number of patients treated Rheumatology Dermatology Gastroenterology TOTAL Abatacept [Orencia] 10 0 0 Adalimumab [Biosimilar] 0 0 0 Adalimumab [Humira] 142 121 77 Apremilast [Otezla] 0 25 0 Baricitinib [Olumiant] 0 0 0 Brodalumab [Kyntheum] 0 0 0 Certolizumab [Cimzia] 23 < 10 0 Dimethyl fumarate [Skilarence] 0 0 0 Etanercept [Enbrel] 22 < 10 0 Etanercept Biosimilar [Benepali or Erelzi] 198 < 10 0 Golimumab [Simponi] 22 0 < 10 Guselkumab [Tremfya] 0 0 0 Infliximab [Remicade] < 10 < 10 < 10 Infliximab Biosimilar [Inflectra, Remsima or Flixabi] 0 0 77 Ixekizumab [Taltz] 0 0 0 Rituximab [Mabthera] 16 < 10 Not known Rituximab Biosimilar [Rixathon or Truxima] < 10 0 Not known Sarilumab [Kevzara] 0 0 0 Secukinumab [Cosentyx] 16 24 0 Tocilizumab [Ro Actemra] 26 < 10 < 10 Tofacitinib [Xeljanz] 0 0 0 Ustekinumab [Stelara] 0 107 < 10 Vedolizumab [Entyvio] 0 0 57